emirates7 - At a recent American Diabetes Association conference, researchers presented findings showing that efsitora—an investigational once-weekly insulin—performed on par with daily insulin regimens in nearly 1,000 adults with type 2 diabetes across three advanced clinical trials.
Each of the studies, which focused on patients at various stages of insulin treatment, demonstrated that efsitora was equally effective as daily insulin in managing HbA1c levels, a key indicator of long-term blood sugar control.
“Once-weekly efsitora could represent a major step forward for people with type 2 diabetes who require insulin, potentially eliminating more than 300 injections annually,” said Jeff Emmick, Senior Vice President of Product Development at Eli Lilly.
One study, published in The New England Journal of Medicine, examined patients initiating insulin therapy for the first time. The other two trials—featured in The Lancet—included individuals already using daily basal insulin degludec, and those taking basal insulin glargine alongside rapid-acting mealtime insulin.
“Efsitora could help streamline insulin treatment and make it less daunting, especially for patients hesitant to begin insulin therapy,” noted Dr. Julio Rosenstock of the University of Texas Southwestern Medical Center, who led one of the trials.
An editorial in The Lancet pointed out that most people newly diagnosed with type 2 diabetes begin with oral medications, but about one-third will need insulin within eight years.
Each of the studies, which focused on patients at various stages of insulin treatment, demonstrated that efsitora was equally effective as daily insulin in managing HbA1c levels, a key indicator of long-term blood sugar control.
“Once-weekly efsitora could represent a major step forward for people with type 2 diabetes who require insulin, potentially eliminating more than 300 injections annually,” said Jeff Emmick, Senior Vice President of Product Development at Eli Lilly.
One study, published in The New England Journal of Medicine, examined patients initiating insulin therapy for the first time. The other two trials—featured in The Lancet—included individuals already using daily basal insulin degludec, and those taking basal insulin glargine alongside rapid-acting mealtime insulin.
“Efsitora could help streamline insulin treatment and make it less daunting, especially for patients hesitant to begin insulin therapy,” noted Dr. Julio Rosenstock of the University of Texas Southwestern Medical Center, who led one of the trials.
An editorial in The Lancet pointed out that most people newly diagnosed with type 2 diabetes begin with oral medications, but about one-third will need insulin within eight years.